NCT07101302 iCANSleep: Smartphone App-Based Insomnia Treatment for Cancer Survivors
| NCT ID | NCT07101302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial University of Newfoundland |
| Condition | Insomnia |
| Study Type | INTERVENTIONAL |
| Enrollment | 146 participants |
| Start Date | 2025-11-04 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 146 participants in total. It began in 2025-11-04 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators will answer the question of whether treating insomnia using the mobile-app-based intervention of Cognitive Behavioural Therapy for Insomnia (CBT-I) for cancer survivors ("iCANSleep") can improve symptoms of insomnia in Canadian cancer survivors compared to a waitlist control group. The investigators will recruit 146 people with insomnia who have completed cancer treatment at least 3 months prior to the study.
Eligibility Criteria
Inclusion Criteria: * Cancer survivors * Over 18 years of age * Lives in Canada * Understands English or French fluently * DSM-5 diagnosis of insomnia * ISI score of 8 or higher * Good performance status as indicated by a score of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale * Access to internet connection * Ownership of smartphone * Fluency using mobile applications. * Individuals with non-hematological malignancies must show no evidence of cancer or clinically stable/inactive disease for a minimum of 3 months prior to enrollment (for individuals with non-metastatic cancer) or be on a stable treatment regimen for the prior 3 months (for individuals with metastatic cancer) to ensure that insomnia is not a direct, acute response to cancer treatment. * Individuals with hematological malignancies must be in remission at the time of recruitment and have completed cancer treatments (e.g., transplant, chemotherapy, immunotherapy, radiotherapy) at least 3 months prior. Exclusion Criteria: * Presence of a sleep disorder other than insomnia that is not adequately treated (e.g., untreated sleep apnea) * Presence of a psychological disorder that is currently untreated or would impair the ability to participate (e.g., bipolar disorder) * Major sensory deficit (e.g., blindness) * Previous experience receiving CBT-I. * The use of medications prescribed for sleep (e.g., hypnotics, sedatives, or antidepressants) will be tracked and adjusted for in the statistical analysis.
Contact & Investigator
Sheila N Garland
PRINCIPAL INVESTIGATOR
Memorial University of Newfoundland
Frequently Asked Questions
Who can join the NCT07101302 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Insomnia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07101302 currently recruiting?
Yes, NCT07101302 is actively recruiting participants. Contact the research team at icansleepapp@gmail.com for enrollment information.
Where is the NCT07101302 trial being conducted?
This trial is being conducted at St. John's, Canada.
Who is sponsoring the NCT07101302 clinical trial?
NCT07101302 is sponsored by Memorial University of Newfoundland. The principal investigator is Sheila N Garland at Memorial University of Newfoundland. The trial plans to enroll 146 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.